Quintiles launches strategic drug development and consulting services in Asia
To help biopharmaceutical companies navigate the complexities of the Asia market, Quintiles has launched two services—Strategic Drug Development and Consulting at Quintiles—to bolster the probability of success in developing and commercializing new medications in the region.
Quintiles’ new Strategic Drug Development organization was designated specifically to help biopharma companies design and implement drug development strategies that take into account the Asia product commercialization opportunity and regulatory hurdles in advance of the standardized development process.
“Beyond simply helping customers meet their needs in the region, our goals are to help define them,” said Amar Kureishi, chief medical officer and head of strategic drug development for Quintiles in Asia. “Today marks the formal service launch, yet our world-class team already has worked with customers on more than 15 projects to transform their development aspirations into reality.”
Also launching is the Consulting at Quintiles practice in Asia to help customers navigate the New Health by linking business strategy, industry expertise and data-driven insights within six practice areas to deliver transformational change. This amalgamation of strategy and operations across regulatory, clinical and commercial serves an unmet demand for comprehensive guidance on how to release the latent value locked in Asian assets and markets.
“Drug development and commercialization in Asia will benefit greatly from new, strategic approaches,” said Christian Gabel, Ph.D., vice president and head of consulting at Quintiles Asia. “Quintiles draws on expertise and lessons learned from 30 years of product development and commercialization in the West to bring differentiated approaches to companies in the East. We are introducing new strategic consulting services to the Asian market, such as our Health Technology Assessment that deploys social networking techniques to anticipate shifts in global market access, and our Market Accelerator end-to-end solution to transpose local drugs to global markets.”